Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 215-572-9
CAS number: 1332-65-6
Table 1. Summary of results of Phase 1.
% of applied dose
Tribasic copper sulphate
Table 2. Summary of results of Phase 2.
In vitro percutaneous absorption of copper from various
formulations through human split-thickness skin membranes was tested in
flow-through diffusion cells. The study was conducted according to OECD
428 (Draft, 2002) and OECD Draft guidance document No. 28 (2002). The
absorption of copper through human skin was negligible, with a worst
case of 0.12 % of the applied dose.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Esta web utiliza cookies para mejorar su experiencia de navegación en nuestros sitios web.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again